Highlights
NASDAQ: TGTX       Tg Therapeuticscmn
Last Price Today's Change   Day's Range   Trading Volume
7.86   +0.29 (3.83%)  7.535 - 8.09  560,339

Overview

 
Avg Volume (4 weeks):1,397,950
4 Weeks Range:5.24 - 8.32
4 Weeks Price Volatility (%):
85.06%
52 Weeks Range:3.32 - 9.38
52 Weeks Price Volatility (%):
74.92%
Average Price Target: 8.00
Price Target Upside/Downside: +0.14

Headlines



No recent Headlines for this stock.


Business Background

TG Therapeutics Inc is a U.S. biopharmaceutical company focused on the development and commercialization of B-cell malignancies and autoimmune disease treatments. The pipeline includes two treatments targeting hematological malignancies and autoimmune diseases: TG-1101 (ublituximab), a glycoengineered monoclonal antibody; and TGR-1202, an orally available PI3K delta inhibitor for various hematologic malignancies. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies, with TG-1101 now entering clinical development for autoimmune disorders. The company also has preclinical programs to develop IRAK4 inhibitors, BET inhibitors, and anti-PD-L1 and anti-GITR antibodies.

  Be the first to like this.
 


 

2836  2761  462  2911 

ActiveGainersLosers
Top 10 Active Counters
 NameLastChange 
 CHK 0.70+0.03 
 FCEL 0.827+0.282 
 AMD 37.36+0.65 
 AABA 19.630.00 
 ET 11.03-0.63 
 GE 11.255-0.165 
 DIS 145.194+6.614 
 BAC 32.72-0.37 
 I 15.22-5.17 
 CLVS 6.255+0.79 
Partners & Brokers